(Q36099482)

12 August 2017

1 reference

title

Infliximab for the treatment of early rheumatoid arthritis (English)

1 reference

12 August 2017

1 reference

2

E William St Clair

1 reference

12 August 2017

Robin C Geletka

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

Expert Opinion on Biological Therapy

12 August 2017

published in

1 reference

12 August 2017

volume

5

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

405-417

1 reference

Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Cause and age at death in a prospective study of 100 patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Monoclonal anti‐TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Infliximab in active early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Infections and anti–tumor necrosis factor α therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Case reports of heart failure after therapy with a tumor necrosis factor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Rheumatoid arthritis and malignant lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: Results from a large observational inception study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.405

21 January 2018

Identifiers

DOI

10.1517/14712598.5.3.405

1 reference

12 August 2017

1 reference